Each vial is formulated with 10mg of high-purity Tirzepatide

Tirzepatide ,  is a dual-action incretin therapy that activates both GIP (glucose dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. By engaging these two metabolic pathways, Tirzepatide helps enhance glucose-dependent insulin release, regulate blood sugar, reduce appetite, and support long-term body-weight management.

Its combined GIP and GLP-1 activity provides a broader metabolic approach than therapies that target GLP-1 alone, such as Semaglutide. Clinical studies have shown meaningful improvements in glycemic control, weight reduction, and metabolic outcomes, while also supporting appetite regulation and metabolic efficiency. This makes Tirzepatide an important treatment option for type 2 diabetes and chronic weight management.